Association of claudin 18.2 expression with outcomes of ramucirumab plus paclitaxel as second-line therapy in advanced gastric cancer

Figure 2 Progression-free survival according to claudin 18. 2 status and multivariable Cox regression analysis for progression-free survival. A: Progression-free survival (PFS) according to claudin 18.2 (CLDN18.2) status. Kaplan-Meier curves for PFS stratified by CLDN18.2 expression. Median PFS was 5.6 months in the CLDN18.2-negative group and 5.3 months in the CLDN18.2-positive group; B: Multivariable Cox regression analysis for PFS. Forest plot depicting adjusted hazard ratios for PFS in the multivariable Cox proportional hazards model including age, Eastern Cooperative Oncology Group performance status, human epidermal growth factor receptor 2 positivity, and liver and peritoneal metastases. CLDN18.2 expression was not significantly associated with PFS. CLDN18.2: Claudin 18.2; ECOG: Eastern Cooperative Oncology Group; HER2: Human epidermal growth factor receptor 2.